학술논문
Patients with high-risk DLBCL benefit from dose-dense immunochemotherapy combined with early systemic CNS prophylaxis
Document Type
Artikel
Author
Source
Blood advances. 4(9):1906-1915
Subject
Language
English
English
English
ISSN
2473-9537